Overview

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cabozantinib with radiation therapy may make the tumors smaller and reduce the amount of normal tissue that needs to be removed.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Exelixis
National Cancer Institute (NCI)